• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results

  • — 6 Nov, 2007
AudioMedica News
AudioMedica News
Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results
Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results
00:00 /
RSS Feed
Share
Link
Embed
Philip Barter
Philip Barter
Gordon Tomaselli
Gordon Tomaselli

REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357

PHILIP BARTER, Heart Research Institute, Sydney, Australia
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore

A randomized double-blind study involving over 15,000 patients at high cardiovascular risk which looked at the new agent torcetrapib (an inhibitor of cholesteryl ester transfer protein, CETP) resulted in higher mortality in the experimental arm. The study compared torcetrapib plus atorvastatin with atorvatstin alone. Inhibition of CETP increases HDL levels and reduces LDL levels and should combat atherosclerosis. Sarah Maxwell spoke with Philip Barter who presented data on the ILLUMINATE trial at the American Heart Association meeting in Orlando.

[audio:https://www.audiomedica.com/podcasting/cardio/071106BarterTomaselliPODCAST.mp3]

You may also like...

  • Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006 Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006 16 Nov, 2006
  • Drug-eluting Stents: No Benefit in Vein Grafts Drug-eluting Stents: No Benefit in Vein Grafts 17 Nov, 2005
  • Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results 6 Nov, 2007
  • Remove Thrombus Before Primary Angioplasty! Remove Thrombus Before Primary Angioplasty! 15 Apr, 2008
  • Previous story Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results
  • Next story TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • New Front Line Standard for Older Patients with Chronic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
    • Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per…
  • Home
  • Cardiovascular
  • Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.